XML 38 R26.htm IDEA: XBRL DOCUMENT
v3.23.2

Strategic Agreements (Details) - USD ($) shares in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | ---
Aug. 31, 2022 | Jul. 31, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Jan. 31, 2020 | Nov. 30, 2019 | May 31, 2018 | Apr. 30, 2018 | Feb. 28, 2018 | Mar. 31, 2017 | Jun. 30, 2023 | Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 10,000,000 |  | $ 0 | $ 10,000,000 |  |
Upon Achievement of Specified Development and Regulatory Milestones | MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |
Microchips Biotech, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of additional consideration |  |  |  |  | $ 1,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued to microchips capital stock holders (in shares) |  |  |  | 700 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash paid to stockholders' representative |  |  |  | $ 75,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset acquisition, contingent consideration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000 | $ 500,000
Microchips Biotech, Inc. | Upon Achievement of Specified Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  | $ 46,500,000 |  |  |  |  |  |  |  |  |  |  |
Current portion of contingent consideration |  |  |  |  |  |  | $ 55,000,000 |  |  |  |  |  |  |  |  |  |  |
ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  |  |  | $ 14,600,000 |  |  |  |  |  |  |
ADVA Tec Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty rate |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |
ADVA Tec Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty rate |  |  |  |  |  |  |  |  |  |  | 1.00% |  |  |  |  |  |  |
Bayer Healthcare License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee paid |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  | 310,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Hennepin License Agreement | Clinical and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments | $ 6,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hennepin License Agreement | Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments | $ 45,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing Agreements | MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |  |  |
Licensing Agreements | Licensed Product or Process for Vaginal or Urological Use | MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000 |  |  |  |
Licensing Agreements | Upon Achieving Certain Commercial Milestones | MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 850,000 |  |  |
Licensing Agreements | Maximum | Upon Achieving Certain Development Milestones | MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  | $ 300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing Agreements | Upon Achievement of Specified Development and Regulatory Milestones | Upon Achieving Certain Commercial Milestones | MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  | $ 1,200,000 |  |  |  |  |  |  |
Licensing Agreements | ADVA Tec Agreement | Upon Reaching Certain Worldwide Net Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  |
Assignment Agreement | Maximum | Upon Achieving Certain Clinical and Regulatory Development Milestones | Hammock Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,100,000 |  |  |
Merger Agreement | Upon Achieving Certain Clinical and Regulatory Development Milestones | Pear Tree Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  |  |  |  |  |  |  | $ 15,500,000 |  |  |  |  |  |  |  |  |  |
Merger Agreement | Upon Achieving Certain Clinical Development, Regulatory And Commercial Milestones | Pear Tree Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  | 3,200,000 |  |  |  |  |  |  |  |  |  |
Pear Tree Pharmaceuticals, Inc. | Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  |  |  |  |  |  |  | $ 47,000,000 |  |  |  |  |  |  |  |  |  |
Juniper Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee paid |  |  |  |  |  |  |  |  | $ 250,000 |  |  |  |  |  |  |  |  |
Potential annual license maintenance fee payments, thereafter |  |  |  |  |  |  |  |  | 100,000 |  |  |  |  |  |  |  |  |
Juniper Pharmaceuticals, Inc | Clinical and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  |  |  |  |  |  |  |  | 13,500,000 |  |  |  |  |  |  |  |  |
Juniper Pharmaceuticals, Inc | Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  |  |  |  |  |  |  |  | $ 30,300,000 |  |  |  |  |  |  |  |  |
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  | $ 18,000,000 |  |  |  |  |  |  |  |
License and Collaboration Agreement | Upon Achieving Certain Commercial Milestones | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |  |
Organon |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee paid |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |
First commercial sale amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,500,000 |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 182,500,000 |  |  |
Sales based milestones amount |  |  |  |  |  |  |  |  |  |  |  | $ 180,000,000 |  |  | 180,000,000 |  |  |
Catalent and MilanaPharm | Licensing Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |

X
- Definition Asset Acquisition, Contingent Consideration + References No definition available. + Details
Name: | dare_AssetAcquisitionContingentConsideration
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Contingent Consideration, Current + References No definition available. + Details
Name: | dare_AssetAcquisitionContingentConsiderationCurrent
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum Potential Milestone Payments + References No definition available. + Details
Name: | dare_MaximumPotentialMilestonePayments
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments, contingent amount. + References No definition available. + Details
Name: | dare_MilestonePaymentsContingentAmount
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments, Contingent Amount, First Commercial Sale Amount + References No definition available. + Details
Name: | dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments, Contingent Amount, Sales Based Milestones Amount + References No definition available. + Details
Name: | dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment of Additional Consideration in Business Combination + References No definition available. + Details
Name: | dare_PaymentOfAdditionalConsiderationInBusinessCombination
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments to Stockholders' Representative in Business Combination + References No definition available. + Details
Name: | dare_PaymentsToStockholdersRepresentativeInBusinessCombination
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of royalty rate. + References No definition available. + Details
Name: | dare_PercentageOfRoyaltyRate
Namespace Prefix: | dare_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Annual License Maintenance Fee Payments, Thereafter + References No definition available. + Details
Name: | dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and development milestone payment. + References No definition available. + Details
Name: | dare_ResearchAndDevelopmentMilestonePayment
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront License Fee, Amount Paid + References No definition available. + Details
Name: | dare_UpfrontLicenseFeeAmountPaid
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_HennepinLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_MergerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_PearTreePharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalDevelopmentRegulatoryAndCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_PearTreePharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dare_OrganonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |